SMS Pharma Q1 FY27 Results: Profit ₹21.13 Cr, MD Reappointed, ₹50 Cr Loan to Subsidiary
SMS Pharmaceuticals Limited reported Q1 FY27 standalone net profit of ₹21.13 Cr, up from ₹18.21 Cr YoY. Consolidated net profit was ₹20.91 Cr. The Board approved the re-appointment of Mr. Ramesh Babu Potluri as Chairman and MD for 5 years from Oct 1, 2026. A loan of up to ₹50 Cr will be given to subsidiary SMS Peptides Private Limited. The 38th AGM is scheduled for Sep 23, 2026.
The financial results show modest year-on-year growth. The re-appointment of the MD and the loan to the subsidiary are significant corporate actions that could impact future operations and governance.
The company reported an increase in both standalone and consolidated net profit for the quarter compared to the previous year. The re-appointment of the MD for a long term and the approval of a loan to a subsidiary are positive developments.
SMS Pharmaceuticals Limited announced its financial results for the first quarter ended June 30, 2026, on July 31, 2026. The company's Board of Directors approved the un-audited standalone and consolidated financial results for the period. The 38th Annual General Meeting (AGM) is scheduled for Wednesday, September 23, 2026, to be held through Video Conference or Other Audio-Visual Means. The Register of Members and Share Transfer Books will remain closed from September 17, 2026, to September 23, 2026, for the AGM. The record date for determining eligible members for dividend for FY 2025-26 has been fixed as September 16, 2026.
In a significant development, the Board approved the re-appointment of Mr. Ramesh Babu Potluri as Chairman and Managing Director for a term of five years, effective from October 1, 2026, to September 30, 2031, subject to shareholder approval. The company also approved a loan of up to ₹50 Crores to its subsidiary, SMS Peptides Private Limited, in one or more tranches, which is also subject to shareholder approval.
For the quarter ended June 30, 2026, the company reported a standalone net profit after tax of ₹2,113.26 Lakhs (₹21.13 Crore), compared to ₹1,820.75 Lakhs (₹18.21 Crore) in the same quarter last year. Consolidated net profit after tax stood at ₹2,090.90 Lakhs (₹20.91 Crore) for the quarter ended June 30, 2026, compared to ₹2,049.05 Lakhs (₹20.49 Crore) in the corresponding quarter of the previous year. The meeting commenced at 3:00 p.m. and concluded at 4:20 p.m.
What to do with a filing like this
SMS Pharmaceuticals Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by SMS Pharmaceuticals Limited. Read the original for the full detail.